Elevated unidentified antibodies in sickle cell anaemia patients receiving blood transfusions in Cape Town, South Africa

K A Thompson,1 BHSc; F Adams,1 MSc; G M Davison,2,3 PhD (Haematology)

1 Western Province Blood Transfusion Service, Pinelands, Cape Town, South Africa
2 Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Cape Town, South Africa
3 Division of Haematology, Faculty of Health Sciences, University of Cape Town, South Africa

Corresponding author: G M Davison (davisong@cput.ac.za)

Background. Sickle cell disease (SCD) is an inherited haemoglobinopathy in which homozygous individuals suffer from numerous complications including vaso-occlusion, infection and haemolytic anaemia. Patients therefore often require blood transfusions, which may lead to elevated levels of alloimmune antibodies. In South Africa (SA), the number of patients with SCD has risen significantly owing to migration and changing demographics, leading to an increased need for blood products. Alloantibody formation which has the potential of significantly reducing the lifespan of the red cell.

Methods. Information on SCD patients receiving blood products between 2010 and 2012, including demographics, number of units transfused and the presence and type of alloantibodies, was collected. The results were compared with those for non-SCD controls who had received a similar number of transfusions.

Results. Of 182 patients analysed, 91 had SCD. Twenty-two percent of the SCD patients and 13.2% of the controls had become alloimmunised (p=0.17, p=0.19, respectively). However, the total number and amount of unidentified antibodies were significantly increased in patients with SCD (p=0.02 and p<0.001, respectively).

Conclusions. This study concluded that patients with SCD develop increased numbers of unidentified antibodies, which may be important in the selection of suitable donors.


Sickle cell disease (SCD) is the most common inherited haemoglobin disorder.1 This haemoglobinopathy is caused by a nucleotide base substitution (adenine – thymine) leading to an amino acid change from glutamic acid to valine on the beta-globin chain.2 The amino acid substitution results in the formation of haemoglobin S (HbS), which has the potential of significantly reducing the lifespan of the red cell. In low oxygen tension environments HbS polymerises, causing elongation of the red cell, which takes on a ‘sickle’ shape. The normal red cell shape may be restored once an optimal oxygen environment returns, but after repeated episodes, the erythrocyte membrane becomes damaged and the sickle shape becomes irreversible.3 The pathophysiology of SCD is complex, with patients suffering from a number of complications including vaso-occlusion and hypoxia leading to painful crises, increased infections, splenic dysfunction, haemolytic anaemia, aplastic crises and organ damage.4

While treatments such as hydroxyurea, gene therapy and stem cell transplantation have all been used with success, blood transfusion remains one of the most important forms of therapy.2,5 The transfusion of blood products aids in restoring the number of normal red cells, improving oxygen-carrying capacity and blood flow, particularly during incidents of severe haemolysis.6

Although blood transfusions are an effective treatment for SCD, there are many risks including alloimmunisation, iron overload and transmission of blood-borne pathogens. The development of alloantibodies in the recipient, probably due to blood group antigenic differences between the donor and the recipient, can lead to delayed transfusion reactions that can be fatal.5 Patients with SCD have been identified as having increased incidences of alloimmunisation despite full compatibility testing between donor and recipient. The most likely cause of this is the receipt of blood products from donors whose red cell antigens are phenotypically different to those of SCD patients, who are mainly of black African descent.5

Objectives
The incidence of SCD in South Africa (SA) has significantly increased as a result of migration and changing demographics. Consequently, the need for blood transfusions and blood products for this group of patients has escalated.8 Cape Town has a diverse population, and as genetic disparity between donor and recipient is the most likely cause of alloantibody development, a study examining the rate of alloimmunisation in patients with SCD receiving blood products in Cape Town was considered important.

Our objectives were to analyse the frequency and distribution of red cell antibodies occurring in SCD patients who had received red blood cell products in Western Cape Province and to compare them with those in a group of non-SCD patients who had received a similar number of transfusions.

Methods
Study design and patient selection
This was a retrospective, cross-sectional study of 182 patients and controls who had received a minimum of one blood transfusion. Data from individuals receiving transfusions between 2010 and 2012 were collected from the Western Province Blood Transfusion Service...
(WPBTS). Information regarding age, clinical diagnosis, number of transfusions and antibodies was collected from the WPBTS's Phoenix database and stored on an Excel spreadsheet, version 2010 (Microsoft, USA). Patients who had required adult red blood cell concentrate, infant red blood cell concentrate, paediatric red blood cell concentrate, leucocyte-reduced red blood cell product or whole blood unit/s were included, while individuals both with and without SCD who had suffered from a recent viral or bacterial infection were excluded. The data from SCD patients were compared with those from a group of randomly selected non-SCD patients who had received a similar number of transfusions.

Ethical approval

Ethical approval was obtained from the Faculty of Health and Wellness Sciences Ethics Committee at the Cape Peninsula University of Technology (ref. no. CPUT/HW-REC 2016D1). Patient information was kept confidential and was anonymised by allocating a number to each patient and removing any personal information such as name, hospital number and identification number. Data collected were not shared with any unauthorised personnel and were stored on a password-protected computer that was only available to the principal investigator.

Data collection

Historical records of patients with 'Sickle cell disease' or 'Sickle cell anaemia' or 'SCA' or 'SCD' or 'Hb SS' or 'Hb SC' were collected. Information including patient age, blood group, antibodies and number of units issued was recorded on an Excel spreadsheet, version 2010. Similar data were collected from a group of patients who had also received blood but did not have SCD. This control group was made up of randomly selected trauma, obstetric and leukaemia patients. As extended phenotyping was started in 2013, data were collected from 2010 to 2012 to avoid any bias and to reflect the true alloimmunisation rate of SCD patients before extended phenotyping began.

Blood grouping and antibody identification

ABO and Rh blood grouping as well as antibody screens were performed on the AutoVue or BioVue systems (Ortho Clinical Diagnostics, USA) using known cells or antisera supplied by Ortho Clinical Diagnostics. If antibody screens were positive, patient samples were sent to the WPBTS Reference Laboratory where the presence of any irregular antibodies was determined using a panel of 12 known-donor red blood cell suspensions to identify antibody or antibodies by a process of elimination. Each of the 12 donor cell suspensions was incubated with patient plasma, and if it was reactive with one of the cell suspensions expressing a particular antigen, the patient was identified as having developed an antibody to the corresponding antigen. If the reaction did not match the expected pattern of expression across the 12 donor cell suspensions, the antibody was referred to as unidentified. The presence of an antibody known to cause transfusion reactions and/or haemolytic disease of the fetus or newborn was considered clinically significant.

Statistical analysis

Data were recorded on an Excel spreadsheet, version 2010, and analysed using Statistica version 13 (Dell, USA). A p-value <0.05 was considered significant when comparing the experimental group against the control data. The parameters were analysed for significance using descriptive analysis (means, ranges and frequencies), Student's t-test and the χ² test. Graphs and tables were created using Excel 2010.

Results

Patient demographics and blood groups

A total of 182 patients who had received at least one blood transfusion were studied. Of these, 91 (50%) had SCD. The other 91 (50%) were trauma, obstetric and leukaemia patients who had received at least one blood transfusion but did not have SCD. The mean age of the SCD patient group was 20.9 years (range 4 - 55), which was significantly lower than that of the control group (mean 45.2 years, range 7 - 94). Although the SCD patients had an increased incidence of alloimmunisation and development of clinically significant antibodies, this was not statistically different from the control group. The distribution of ABO blood group and Rh antigens was similar across the two groups, but patients with SCD had a significantly lower incidence of blood group A Rh positivity (p=0.047). The demographic data and blood group results are shown in Table 1.

Frequency of alloantibodies

The alloimmunisation rate with clinically significant antibodies was higher in the SCD patients (15.4%) than in the control group (9.9%), but this difference was not significant (p=0.172). Regardless of antibody type, 22.0% of the patient group and 13.2% of the control group became alloimmunised (p=0.119), with the median number of transfusions being higher in the control group (3.8) than in the patient group (2.8). However, a significantly increased number of total antibodies was detected in the SCD patients compared with the controls (p=0.016), and the number of unidentified antibodies present in the SCD group v. the controls was also significantly elevated (p<0.001) (Table 2).

Discussion

The objectives of this study were to document the frequency and distribution of allogeneic red cell antibodies in SCD patients receiving blood products in the Western Cape. Although the rate of alloimmunisation was similar to that of the controls (p=0.119), the results revealed significantly elevated numbers of total antibodies (p=0.016), of which many were unidentified (p<0.001).

Of the 91 SCD patients, 22.0% had been alloimmunised, and although this figure was not significantly different to that of the control group, it was higher than reported in many other studies in the literature, which range from 6.9% to 74%.[16-25] The rate of alloimmunisation is influenced by a number of factors including history of pregnancy, number of blood transfusions, age at first transfusion, sex and genetics.[15,16,18] In a study of SCD patients who had been fully cross-matched,[17] it was reported that individuals receiving more than 8.9 units of blood had a significantly higher alloimmunisation rate (59%) than those receiving less (15%). In our study, the median number of transfused units in SCD patients (2.77) was not significantly different to that in the control group (3.8), but the median age of the SCD patients was significantly lower (p=0.001). Many younger children have underdeveloped immune responses, and this may influence the recognition of foreign antigens and the consequent development of allogeneic antibodies.[16] Since their underdeveloped immune systems may not recognise donor antigens, it is therefore envisaged that as these children age and receive more transfusions, the rate of alloimmunisation will increase.

Despite the lower number of transfused units, the patients with SCD had a significantly increased number of total allogeneic antibodies (p=0.016), of which many were unidentified (p<0.001). These data must be interpreted in context, however, as although there was an increase in unidentified antibodies, the total number of clinically
significant alloantibodies in the two groups was not statistically different. Many of the detected antibodies were unidentified and had possibly developed to antigens not usually seen in our region.

SCD is prevalent throughout sub-Saharan Africa, the Middle East and India. The majority of patients with SCD in Cape Town originate from Africa, in particular the Democratic Republic of the Congo.

One of the major causes of the development of allogeneic antibodies and alloimmunisation is the difference in the antigenic phenotype between the donor and the recipient. In areas where there is ethnic diversity and the donor population is racially different to the recipients, the alloimmunisation rate is significantly increased.

This theory appears to be supported by other studies in countries with more homogeneous populations such as Uganda, where alloimmunisation rates are lower at 6%. In the WPBTS integrated report of 2017-2018 indicated that 59% of donors were white, 34% of mixed ancestry, 1% Asian and 6% of black African descent. The increased number of unidentified antibodies may therefore be linked to antigenic differences resulting from the genetic and ethnic diversity in the region.

Patients with SCD have a number of additional factors that could predispose them to developing alloantibodies. These include clinical complications, an abnormal immune response, and polymorphisms of the immune regulatory gene TRIM21. In addition, SCD has often been described as a chronic inflammatory disorder with increased inflammatory cytokines that could influence the rate of alloimmunisation and the development of autoantibodies.

Table 1. Patient and control group characteristics

<table>
<thead>
<tr>
<th>Blood group system</th>
<th>Patients (N=91)</th>
<th>Controls (N=91)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (range)</td>
<td>20.9 (4 - 55)</td>
<td>45.2 (7 - 94)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total units transfused</td>
<td>252</td>
<td>346</td>
<td>0.197</td>
</tr>
<tr>
<td>Mean*</td>
<td>2.77</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td>Range*</td>
<td>1 - 17</td>
<td>1 - 45</td>
<td></td>
</tr>
<tr>
<td>Clinically significant antibodies, n (%)</td>
<td>14 (15.4)</td>
<td>8 (8.8)</td>
<td>0.172</td>
</tr>
<tr>
<td>Rate of alloimmunisation, n (%)</td>
<td>20 (22.0)</td>
<td>12 (13.2)</td>
<td>0.119</td>
</tr>
<tr>
<td>ABO and Rh, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O positive</td>
<td>49.5</td>
<td>41.7</td>
<td>0.377</td>
</tr>
<tr>
<td>B positive</td>
<td>20.9</td>
<td>14.3</td>
<td>0.289</td>
</tr>
<tr>
<td>A positive</td>
<td>16.5</td>
<td>30.8</td>
<td>0.047</td>
</tr>
<tr>
<td>AB positive</td>
<td>3.3</td>
<td>4.4</td>
<td>0.705</td>
</tr>
<tr>
<td>Unidentified†</td>
<td>9.8</td>
<td>3.3</td>
<td>0.083</td>
</tr>
<tr>
<td>B negative</td>
<td>0</td>
<td>3.3</td>
<td>0.083</td>
</tr>
<tr>
<td>O negative</td>
<td>0</td>
<td>3.3</td>
<td>0.083</td>
</tr>
</tbody>
</table>
| *Means and ranges of units transfused per patient.
†Patients who expressed blood group antigens not identified by the routine 12-donor red cell suspensions.

Table 2. Frequency of antibodies

<table>
<thead>
<tr>
<th>Blood group system</th>
<th>Alloantibody specificity</th>
<th>Number of alloantibodies</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rh</td>
<td>D, E, e, C, c</td>
<td>2, 3, 0, 1, 1</td>
<td>0, 8, 1, 3, 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kell</td>
<td>K</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>MNSSs</td>
<td>S, s</td>
<td>1, 0</td>
<td>2, 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoantibodies</td>
<td>Fyb</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Duffy</td>
<td>0</td>
<td>1</td>
<td>0.318</td>
</tr>
<tr>
<td>Other*</td>
<td>4</td>
<td>11</td>
<td>0.097</td>
</tr>
<tr>
<td>Unidentified</td>
<td>1</td>
<td>14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total antibodies</td>
<td>19</td>
<td>51</td>
<td>0.016</td>
</tr>
<tr>
<td>Clinically significant</td>
<td>14</td>
<td>26</td>
<td>0.162</td>
</tr>
</tbody>
</table>
| SCD = sickle cell disease.
*Other antibodies detected in the SCD group were one each of anti-HI, Kpa, Xga, Lea, Leb, Lu a, Cw, and Rh34 and three anti-Ms. In the control group, one each of anti-HI, A1, f and Auto I were detected.

According to the 2011 population census of the Western Cape, the population had increased by 28% since the previous census in 2001 and the increase was largely attributed to migration from other provinces and outside the country. The Western Cape has a total of 5.8 million people, which can be broken down into those of mixed ancestry (48.8%), black Africans (32.8%), Asians (2%) and whites (15%). In contrast, although the WPBTS recruits donors across all ethnic groups residing in the Western Cape, the profile of donors is very different to the demographics of the province, and in particular those suffering from SCD. The WPBTS integrated report of 2017-2018 indicated that 59% of donors were white, 34% of mixed ancestry, 1% Asian and 6% of black African descent. The increased number of unidentified antibodies may therefore be linked to antigenic differences resulting from the genetic and ethnic diversity in the region.

Patients with SCD have a number of additional factors that could predispose them to developing alloantibodies. These include clinical complications, an abnormal immune response, and polymorphisms of the immune regulatory gene TRIM21. In addition, SCD has often been described as a chronic inflammatory disorder with increased inflammatory cytokines that could influence the rate of alloimmunisation and the development of autoantibodies.
study there was no difference in the development of autoantibodies between the two groups. Tests evaluating levels of inflammation were not available, so this association could not be made.

The result of alloimmunisation is the development of delayed haemolytic transfusion reactions due to the reaction of alloengenic antibodies to antigens expressed on the donor red cells. These antibodies are often not detected prior to the transfusion owing to low titres and lack of transfusion records. In addition, it is thought that the proinflammatory environment present in SCD promotes increased haemolysis of the donor cells and causes the patient’s sickled red cells to adhere to the vessel wall, causing vaso-occlusion. [52]

These reactions can be life threatening and may be missed as they often occur up to 2 weeks after the transfusion has taken place. It is therefore important for clinicians to monitor patients who have received blood products carefully, and for blood transfusion services to implement strategies that attempt to prevent these reactions from occurring. These should include the transfusion of leucodepleted red cells and extended antibody screening. Recruitment of donors of black African descent and from pop-upulation groups representative of patients with SCD is also required.

Study limitations

A limitation of this study was that full demographic and diagnostic information regarding the haemoglobin variant was not available. It is well recognised that certain haemoglobin variants are associated with increased alloimmunisation rates. For example, individuals with the homozygous HbSS and HbSbα thalassaemia variants have higher incidences of alloimmunisation than those with HbSC. [23] In Cape Town, HBC and thalassaemia have been identified in individuals of mixed ancestry and in those of Indian and Mediterranean descent. [9]

In order to understand the above findings fully, further studies would therefore need to include full demographic and diagnostic criteria.

Conclusions

Despite the above limitation, this study has been able to conclude that patients with SCD develop significantly elevated numbers of alloengenic antibodies, of which many are unidentified. The disparity between donor and patient red cell phenotypes is the most likely cause. The Western Cape has many diverse population groups, and as migration from other parts of the African continent is likely to continue, the incidence of diseases such as SCD will continue to rise. The blood transfusion services throughout SA have an important role to play in the treatment and survival of these patients, and will therefore be required to address these challenges. New strategies to recruit donors from all population groups, including those from Central Africa, and more comprehensive antibody screening may be required.

Since completion of this study, extended phenotyping for SCD has been introduced and further research investigating the impact of these strategies is under way.

Declaration

This publication and study formed part of the requirement for KAT’s BSc (Medical Laboratory Science) degree.

Acknowledgements

The authors thank the WPBTS for data retrieval and Dr Corrie Uys for her assistance with the statistical analysis.

Author contributions.

KAT: substantial contributions to conception and design, analysis of data and approval of manuscript to be published. FA: substantial contributions to conception and design, analysis of results, supervision of KAT, and final approval of the version to be published. GMD: substantial contributions to conception and design, drafting the article, supervision of student and final approval of the version to be published.

Funding

None.

Conflicts of interest.

None.


Accepted 23 April 2019.